Background. Carbapenem-resistant Enterobacteriaceae (CRE) are associated with considerable mortality. As mechanisms of carbapenem resistance are heterogeneous, it is unclear if mortality differs based on resistance mechanisms. We sought to determine whether CRE resistance mechanism determination is prognostically informative.
Resistance to carbapenem antibiotics is recognized globally as one of the most pressing concerns facing the healthcare community [1] . Carbapenem-resistant Enterobacteriaceae (CRE) bacteremia is associated with considerable mortality, approaching 60% in published studies [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . Mechanisms of carbapenem resistance are heterogeneous. Chiefly, resistance can be mediated via carbapenemase production (CP-CRE) or via production of extended-spectrum β-lactamases (ESBLs) and/or AmpC cephalosporinases (AmpC) combined with altered membrane permeability (non-CP-CRE) [15] .
Available studies evaluating outcomes associated with CRE bacteremia generally analyze CRE as a single composite category without discriminating between underlying resistance mechanisms [2, 4, 5, 10] . To date, there have been no studies comparing the clinical outcomes of CP-CRE and non-CP-CRE bacteremia.
Understanding the implications of CRE resistance mechanism heterogeneity has assumed newfound clinical relevance as reliable phenotypic and genotypic carbapenemase assays are increasingly becoming available. Clear differences in outcomes between CP-CRE and non-CP-CRE infections would underscore the importance of delineating underlying resistance mechanisms in CRE as this may impact antibiotic treatment decisions (eg, prioritizing who should receive newer CP-CRE active antibiotic agents). Conversely, if differences do not exist, then additional resistance testing may not be necessary to guide clinical management. Our objective was to compare mortality in patients with CP-CRE and non-CP-CRE bacteremia in order to determine whether CRE resistance mechanism determination is prognostically informative.
METHODS

Study Population
We conducted a retrospective, observational cohort study including 83 unique patients with monomicrobial CRE bacteremia who were hospitalized at the Johns Hopkins Hospital between March 2013 and April 2016. Six patients with CRE in their bloodstream during this time period were excluded as their clinical isolates could not be located for additional genotypic testing. Patient data were collected via chart review and included the following: demographics, preexisting medical conditions, source of bacteremia and source control measures, microbiological data, antibiotic therapy, and outcomes data. Source control was defined as the removal of infected hardware or drainage of infected fluid collections within the first 7 days of receiving antibiotic therapy. Consistent with the current Centers for Disease Control and Prevention definition, CRE was defined as Enterobacteriaceae isolates demonstrating resistance to any carbapenem (ertapenem, meropenem, imipenem, and/or doripenem), based on antimicrobial susceptibility testing (AST).
Active empiric antibiotic therapy was defined as at least 1 antibiotic with in vitro activity, based on AST, against the isolate within 24 hours of the time the first positive blood culture was obtained. For meropenem minimum inhibitory concentrations (MICs) of ≤4 µg/mL, standard-infusion meropenem administered at 2 grams every 8 hours was considered active based on existing pharmacokinetic-pharmacodynamic studies [16, 17] . Meropenem treatment for MICs of 8 µg/mL was considered active if extended-infusion meropenem (2 grams every 8 hours over at least 3 hours) was administered, as modeling of extended-infusion strategies suggests that reasonable target attainment can be anticipated with meropenem MICs of up to 8 µg/mL and possibly 16 µg/mL [16, 17] . Active directed antibiotic therapy was defined as at least 1 antibiotic with in vitro activity against the isolate any time after AST results were available, up to 7 days after the first positive blood culture was obtained.
The primary exposure was identification of a CP-CRE via carbapenemase gene detection in a CRE isolate. The primary outcome was 14-day mortality, with day 1 as the day the first positive blood culture was collected. Fourteen-day mortality was selected as the primary endpoint, as it was thought to be most reflective of death attributable to CRE bacteremia. Secondary outcomes included 30-day mortality and 30-day recurrence of CRE bacteremia. The Johns Hopkins University School of Medicine Institutional Review Board approved this study, with a waiver of informed consent.
Resistance Mechanism Identification
Bacterial genus, species, and AST results were identified using matrix-assisted laser-desorption ionization time-of-flight mass spectrometry (Bruker Daltonics Inc., Billerica, Massachusetts) and the BD Phoenix Automated System (BD Diagnostics, Sparks, Maryland). For isolates that demonstrated resistance to any carbapenem antibiotic, using the Clinical Laboratory and Standards Institute (CLSI) criteria, carbapenem MICs were confirmed with Etests (bioMérieux, Durham, North Carolina). Carbapenem resistance was defined as an ertapenem MIC ≥2 µg/mL and meropenem and/or imipenem MIC ≥4 µg/mL.
Genomic DNA was extracted from isolates using the DNeasy Blood & Tissue Kit (QIAGEN, Inc., Valencia, California). Identification of β-lactamase-encoding genes was assessed using a comprehensive DNA microarray-based assay, the Check-MDR CT103XL kit (CheckPoints, Wageningen, the Netherlands). The CheckPoints assay can detect the following plasmid-mediated β-lactamase genes: ESBLs: Of note, the MHT was performed on CRE isolates during the study period to distinguish CP-CRE and non-CP-CRE for infection control purposes. However, The Johns Hopkins Hospital Antibiotic Treatment Guidelines [18] do not differentiate treatment recommendations for CP-CRE and non-CP-CRE. All molecular testing, as well as the MβL Etest, Carba NP test, and a repeat MHT test, was performed retrospectively. Clinicians were unaware of carbapenemase gene results when they selected antibiotic therapy for CRE bacteremic patients.
Statistical Methods
Descriptive statistics for patient variables were calculated using median (interquartile range [IQR] A priori confounders to be included in the multivariable model for the primary outcome were day 1 Pitt bacteremia score ≥4 [19] , receipt of combination antibiotic therapy, receipt of active in vitro empiric antibiotic therapy, and receipt of active in vitro directed antibiotic therapy. Covariates found to have a P value <.10 on univariable analysis and that resulted in a 10% or greater change in the parameter estimate of the CP-CRE group were retained in the final multivariable logistic regression models for each outcome. All tests were 2-tailed, and P values ≤ .05 were used for statistical significance testing. Analyses were performed using the STATA 13.0 (Stata Corp) statistical package.
RESULTS
Microbiological Characteristics
There were 83 unique episodes of monomicrobial CRE bacteremia during the study period: 37 (45%) CP-CRE and 46 (55%) non-CP-CRE (Table 1) . Although the ratio of CP-CRE and non-CP-CRE bacteremia across the study years was relatively constant, the overall proportion of CRE bacteremia steadily increased and more than tripled over the study period: 2.01 per 100 episodes of Enterobacteriaceae bacteremia in 2013, 3.66 per 100 in 2014, 6.50 per 100 in 2015, and 7.00 per 100 in 2016. AST results for CRE bloodstream isolates are displayed in Table 2 . For CP-CRE bacteremic isolates, the predominant genus and species were Klebsiella spp. (76%) and Enterobacter spp. (19%); there was 1 (3%) isolate each of Escherichia coli and Citrobacter amalonaticus. For non-CP-CRE, the genus and species distribution was slightly more diverse but largely reversed: 59% Enterobacter spp., 30% Klebsiella spp., 7% E. coli, and 1 each (2%) of Proteus mirabilis and Serratia marcescens. The majority of CP-CRE isolates were bla KPC (92%), followed by bla NDM (5%) and bla OXA-48-type (3%; ( Table 1) . CP-CRE isolates were more likely to require meropenem MICs of ≥16 µg/mL for growth inhibition, while non-CP-CRE isolates were more likely to require meropenem MICs of ≤1 µg/mL (P value < .001;), Table 2 ).
For 21 isolates categorized in the non-CP-CRE group, no β-lactamase genes (ie, carbapenemase, ESBL, pAmpC) were identified. The CheckPoints assay was repeated on these isolates by different trained users, with consistent results. These isolates (n = 16), Klebsiella pneumoniae (n = 3), Serratia marcescens (n = 1), and Proteus mirabilis (n = 1).
also yielded negative results by MHT, MβL Etest, and the Carba NP test, indicating they were unlikely to be carbapenemase producing. The organisms involved were as follows: Enterobacter spp. (n = 16), K. pneumoniae (n = 3), S. marcescens (n = 1), and P. mirabilis (n = 1). The median meropenem MIC for this group was 1 µg/mL (IQR, 1-2 µg/mL), meeting criteria for carbapenem resistance generally because of ertapenem resistance.
Baseline and Treatment Characteristics
The CP-CRE and non-CP-CRE groups were well balanced on demographic information and most preexisting medical conditions (Table 3) . CP-CRE patients were less likely to receive active empiric antibiotic therapy compared with patients with non-CP-CRE bacteremia, although this difference did not achieve statistical significance (32% vs 52%, P = .07). Excluding the 9 patients who expired within 3 days of bacteremia onset, which was before AST results were available to treating clinicians, patients with CP-CRE were less likely to receive active directed antibiotic therapy compared with patients in the non-CP-CRE group (84% vs 100%; P < .001). A carbapenem-containing regimen was administered to 84% of patients in the CP-CRE group and 95% (P = .13) in the non-CP-CRE group. All patients in the cohort who received meropenem received 2 grams every 8 hours, in compliance with the Johns Hopkins Antibiotic Treatment Guidelines. Additionally, all patients with meropenem MICs ≥8 µg/mL who received meropenem received it as an extended infusion. CP-CRE bacteremic patients were more likely to receive combination antibiotic therapy (78% vs 30%, P < .001) and for a longer duration of time. CP-CRE and non-CP-CRE patients received combination therapy for a median of 5 (IQR, 1-13) and 0 (IQR, 0-2) days, respectively (P < .001). Empiric and directed antibiotic regimens are described in Supplemental Table 1.
14-Day and 30-Day Mortality
A total of 18 (22%) patients died within 14 days, including 12 (32%) in the CP-CRE group and 6 (13%) in the non-CP-CRE group. No correlation was observed with increasing meropenem MICs and mortality ( The majority of these are presumed to be derepressed, chromosomally mediated ampC β-lactamases. Abbreviations: CP, carbapenemase-producing; CRE, carbapenem-resistant Enterobacteriaceae; IQR, interquartile range. a Inappropriate source control defined as retained infected hardware or lack of drainage of infected fluid collections within the first 7 days of antibiotic therapy.
Table 3. Baseline Characteristics of Patients and Clinical Isolates With Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae (CP-CRE) and Non-CP-CRE Bacteremia
b "Immunocompromised" is a composite category of conditions listed below this heading; the conditions listed are not mutually exclusive.
c At least 1 antibiotic demonstrating in vitro activity to the isolate recovered within 24 hours of the time the first positive blood culture was obtained; meropenem minimum inhibitory concentrations (MICs) up to 8 µg/mL considered active in vitro as modeling of extended infusion-strategies suggest that reasonable target attainment can be anticipated with MICs up to 8-16 µg/mL. d At least 1 antibiotic demonstrating in vitro activity to the isolate any time after antibiotic susceptibility results were available, up to 7 days after the first positive blood culture was obtained; meropenem minimum inhibitory concentrations up to 8 µg/mL were considered active in vitro (excluding 5 patients in the CP-CRE group and 4 patients in the non-CP-CRE group who died in the first 72 hours, before an antibiotic susceptibility test would have returned).
Because of the notable differences in MIC distributions and in vitro activity of the empiric and directed antibiotic regimens between the CP-CRE and non-CP-CRE groups, we repeated the analysis and restricted the cohort to patients infected with CRE bacteremia with meropenem MICs ≤4 µg/mL. There were 7 (35%) deaths and 6 (14%) deaths in the CP-CRE and non-CP-CRE groups within 14 days (and 9 [45%] and 8 [18%] deaths within 30 days). Because all patients in this restricted cohort who survived until day 3 received appropriate directed antibiotic therapy, this variable was no longer included in the multivariable analysis. Adjusting for receipt of active empiric therapy and Pitt bacteremia score ≥4, the aOR was 3.39 times higher (95% CI, 0.85-12.80; P = .08) and 3.79 times higher (95% CI, 1.02-14.02; P = .04) for the CP-CRE group when evaluating 14-day and 30-day mortality, respectively.
30-Day Recurrent CRE Bacteremia
Excluding the 20 patients who died within 30 days without first experiencing a bacteremia recurrence, there were 12 episodes of recurrent CRE bacteremia within 30 days: 9 (38%) in the CP-CRE group and 3 (8%) in the CP-CRE non-CP-CRE group (P = .003). After adjusting for receipt of active empiric therapy, active directed therapy, and appropriate source control measures, CP-CRE patients remained at increased odds of bacteremia recurrence within 30 days relative to non-CP-CRE patients (OR = 2.67; 95% CI, 1.54-13.2). No other variables in multivariable analysis were independently associated with CRE bacteremia recurrence within 30 days.
DISCUSSION
Our results suggest that patients with CP-CRE bacteremia have about 4 times the odds of dying within 14 days compared to patients with non-CP-CRE bacteremia after accounting for severity of illness on day 1 of bacteremia, underlying medical conditions, and antibiotic treatment administered. These findings suggest that CP-CRE isolates may be more virulent than non-CP-CRE mechanisms of resistance. Because more antibiotic agents with activity against CP-CRE are in advanced phases of drug development [20] , distinguishing CP-CRE from non-CP-CRE will be increasingly important as patients infected with the former should be prioritized for newer agents. If these newer agents are indiscriminately prescribed for patients infected with CRE, resistance to them may be accelerated, rendering them ineffective.
Previous studies have demonstrated mortality from CRE bacteremia ranging from approximately 20% to 70% [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . Considerable variability in definitions of carbapenem-resistance, limited to no description of the mechanisms of carbapenem resistance included, variability in treatment administered, differences in casemix data, and variability in outcome definitions, make comparisons between studies difficult. Villegas and colleagues compared clinical outcomes of patients with CP bacteremia and non-CP bacteremia in a multicenter, observational study across 7 Latin American countries [21] . They found that patients with CP bacteremia had 4 times the odds of death within 28 days compared with non-CP bacteremia. However, more than 90% of patients in the non-CP group had isolates susceptible to carbapenems using the current CLSI breakpoints. To our knowledge, no previous studies have compared outcomes of patients with CP-CRE and non-CP-CRE bacteremia.
The aggressiveness of CP-CRE pathogens is highlighted by their ability to hydrolyze carbapenems to a greater extent compared with non-CP-CRE. There were notable differences in the carbapenem MIC distributions in our cohort. For example, CP-CRE isolates were more likely to have meropenem MICs ≥16 µg/mL compared with non-CP-CRE isolates (38% vs 2%). CP-CRE were also less likely to be susceptible to other non-β-lactam agents considered for the treatment of CRE, such as aminoglycosides, fluoroquinolones, tigecycline, and polymixins. Because of these resistance profiles, empiric therapy regimens were less likely to be active against CP-CRE isolates. Additionally, clinicians were more likely to resort to agents such as polymixins and tigecycline as directed therapy for CP-CRE bacteremia. Because of the substantial differences in MIC distributions between CP-CRE and non-CP-CRE and differences in the in vitro activity of the antibiotic regimens prescribed, we repeated the analysis and limited inclusion to patients with meropenem MICs ≤4 µg/mL and still observed differences in mortality between CP-CRE and non-CP-CRE. This suggests that underlying microbial characteristics may have an important role in poor outcomes of patients with CP-CRE infections. For 21 patients categorized in the non-CP-CRE group growing Enterobacter spp., K. pneumoniae, S. marcescens, and P. mirablis, no β-lactamase gene was identified. Like all molecular methods, this assay can only recognize β-lactamase genes that have been previously characterized and would be unable to identify new targets. However, the CheckPoints assay used in this study includes a comprehensive group of narrow-spectrum β-lactamases, ESBLs, pAmpCs, and carbapenemases, and it would be unlikely that a large number of novel, unrelated (as AST patterns differed in these 21 isolates) β-lactamase genes were present. Additionally, MHT, MβL Etest, and Carba NP testing were negative, suggesting that these isolates were unlikely to harbor carbapenemases. Rather, we suspect that the most likely explanation was induction of chromosomally mediated AmpC cephalosporinases in addition to outer membrane protein mutations, particularly as 76% of these isolates were Enterobacter spp., the organisms most commonly associated with chromosomally mediated AmpC inducible resistance. The chromosomal ampC gene is not included in the Check-MDR CT103XL assay. ampC genes have also been identified with other Enterobacteriaceae [22] , including S. marcensens [23, 24] . As whole genome sequencing was not performed on these 21 isolates, we cannot say with any certainty what the mechanisms of carbapenem resistance were, but feel that misclassification bias was unlikely based on the negative CheckPoints, MHT, MβL, Carba NP, and meropenem MIC results of these isolates.
There are several limitations with this work. First, although we attempted to include all variables that have been identified as being associated with poor outcomes for patients with CRE bacteremia, we cannot exclude the possibility that there was residual confounding that we did not account for that influenced treatment outcomes between CP-CRE and non-CP-CRE cases. Second, our limited sample size precluded analyses of certain subgroups, such as differences that may exist due to bacterial genus and species, differences in carbapenemase-specific genes, and differences in polymixin dosing. Additionally, this work included patients from a single center in the United States. Although we anticipate that our carbapenemase-gene distribution is similar to those in most US institutions (ie, mainly bla KPC ) [25, 26] , it will differ from those in other regions of the world where bla NDM or bla OXA-48-types predominate [1], compromising generalizability. We encourage others to repeat these analyses with a larger cohort to both explore these lingering issues and determine if our results are reproducible. Finally, we did not characterize the plasmids that carry the β-lactamase genes identified in this study. It is possible that these plasmids harbor virulence characteristics that are independent of the actual carbapenemase genes, resulting in poorer outcomes of patients with CP-CRE infections. Future work to characterize the associated plasmids will be helpful in exploring this hypothesis.
These limitations notwithstanding, our findings suggest that bacteremia due to CP-CRE may be independently associated with unfavorable patient outcomes compared with non-CP-CRE bacteremia. It may not be sufficient to determine solely whether a clinical isolate is carbapenem resistant, as is the practice at most US healthcare institutions. Rather, understanding whether isolates are carbapenemase producers may be necessary to guide treatment decisions. This is particularly relevant as newer agents with activity against CP-CRE are anticipated to be available in upcoming years and must be prioritized for patients infected with pathogens with confirmed carbapenemase production. It may be some time before rapid, accurate, user-friendly, and affordable options for detecting the comprehensive list of carbapenemase genes present in common Enterobacteriaceae become available to the average diagnostic laboratory. However, we believe our work gives credence to the potential for precision medicine, the approach for disease treatment that accounts for individual variability in genes, among other unique characteristics, to ultimately result in improved patient outcomes.
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